instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pleural effusion'. | Lurbinectedin-Induced Tumor Lysis Syndrome in Small Cell Neuroendocrine Cancer of the Cecum: A First-Ever Case Report.
BACKGROUND Lurbinectedin (Lurbi) was first approved in June 2020 for metastatic small cell lung cancer (SCLC) patients with progression following platinum-based chemotherapy. Extrapulmonary small cell ... | ATEZOLIZUMAB, CARBOPLATIN, ETOPOSIDE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN CALCIUM | DrugsGivenReaction | CC BY-NC-ND | 34125741 | 20,204,241 | 2021-06-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Small intestinal obstruction'. | Lurbinectedin-Induced Tumor Lysis Syndrome in Small Cell Neuroendocrine Cancer of the Cecum: A First-Ever Case Report.
BACKGROUND Lurbinectedin (Lurbi) was first approved in June 2020 for metastatic small cell lung cancer (SCLC) patients with progression following platinum-based chemotherapy. Extrapulmonary small cell ... | ATEZOLIZUMAB, CARBOPLATIN, ETOPOSIDE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN CALCIUM | DrugsGivenReaction | CC BY-NC-ND | 34125741 | 20,204,241 | 2021-06-14 |
What was the dosage of drug 'ATEZOLIZUMAB'? | Lurbinectedin-Induced Tumor Lysis Syndrome in Small Cell Neuroendocrine Cancer of the Cecum: A First-Ever Case Report.
BACKGROUND Lurbinectedin (Lurbi) was first approved in June 2020 for metastatic small cell lung cancer (SCLC) patients with progression following platinum-based chemotherapy. Extrapulmonary small cell ... | UNK (3 CYCLES MAINTENANCE) | DrugDosageText | CC BY-NC-ND | 34125741 | 20,204,241 | 2021-06-14 |
What was the dosage of drug 'CARBOPLATIN'? | Lurbinectedin-Induced Tumor Lysis Syndrome in Small Cell Neuroendocrine Cancer of the Cecum: A First-Ever Case Report.
BACKGROUND Lurbinectedin (Lurbi) was first approved in June 2020 for metastatic small cell lung cancer (SCLC) patients with progression following platinum-based chemotherapy. Extrapulmonary small cell ... | UNK (4 CYCLES) | DrugDosageText | CC BY-NC-ND | 34125741 | 20,204,241 | 2021-06-14 |
What was the dosage of drug 'ETOPOSIDE'? | Lurbinectedin-Induced Tumor Lysis Syndrome in Small Cell Neuroendocrine Cancer of the Cecum: A First-Ever Case Report.
BACKGROUND Lurbinectedin (Lurbi) was first approved in June 2020 for metastatic small cell lung cancer (SCLC) patients with progression following platinum-based chemotherapy. Extrapulmonary small cell ... | UNK (4 CYCLES) | DrugDosageText | CC BY-NC-ND | 34125741 | 20,204,241 | 2021-06-14 |
What was the dosage of drug 'FLUOROURACIL'? | Lurbinectedin-Induced Tumor Lysis Syndrome in Small Cell Neuroendocrine Cancer of the Cecum: A First-Ever Case Report.
BACKGROUND Lurbinectedin (Lurbi) was first approved in June 2020 for metastatic small cell lung cancer (SCLC) patients with progression following platinum-based chemotherapy. Extrapulmonary small cell ... | UNK (3 CYCLES) | DrugDosageText | CC BY-NC-ND | 34125741 | 20,204,241 | 2021-06-14 |
What was the dosage of drug 'IRINOTECAN'? | Lurbinectedin-Induced Tumor Lysis Syndrome in Small Cell Neuroendocrine Cancer of the Cecum: A First-Ever Case Report.
BACKGROUND Lurbinectedin (Lurbi) was first approved in June 2020 for metastatic small cell lung cancer (SCLC) patients with progression following platinum-based chemotherapy. Extrapulmonary small cell ... | UNK (3 CYCLES) | DrugDosageText | CC BY-NC-ND | 34125741 | 20,204,241 | 2021-06-14 |
What was the dosage of drug 'LEUCOVORIN CALCIUM'? | Lurbinectedin-Induced Tumor Lysis Syndrome in Small Cell Neuroendocrine Cancer of the Cecum: A First-Ever Case Report.
BACKGROUND Lurbinectedin (Lurbi) was first approved in June 2020 for metastatic small cell lung cancer (SCLC) patients with progression following platinum-based chemotherapy. Extrapulmonary small cell ... | UNK (3 CYCLES) | DrugDosageText | CC BY-NC-ND | 34125741 | 20,204,241 | 2021-06-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug resistance'. | Clinical and experimental phenotype of azole-resistant Aspergillus fumigatus with a HapE splice site mutation: a case report.
BACKGROUND
The recent increase in cases of azole-resistant Aspergillus fumigatus (ARAf) infections is a major clinical concern owing to its treatment limitations. Patient-derived ARAf occurs aft... | ITRACONAZOLE, VORICONAZOLE | DrugsGivenReaction | CC BY | 34126952 | 19,690,566 | 2021-06-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cerebral infarction'. | Anti-neutrophil cytoplasmic antibody-associated vasculitis accompanied by type II heparin-induced thrombocytopenia resulting in asymptomatic cerebral infarction: a case report.
Heparin-induced thrombocytopenia (HIT) involves platelet activation and aggregation caused by heparin or HIT antibodies associated with poor su... | CYCLOPHOSPHAMIDE, HEPARIN SODIUM, METHYLPREDNISOLONE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34126959 | 19,588,402 | 2021-06-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Anti-neutrophil cytoplasmic antibody-associated vasculitis accompanied by type II heparin-induced thrombocytopenia resulting in asymptomatic cerebral infarction: a case report.
Heparin-induced thrombocytopenia (HIT) involves platelet activation and aggregation caused by heparin or HIT antibodies associated with poor su... | CYCLOPHOSPHAMIDE, HEPARIN SODIUM, METHYLPREDNISOLONE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34126959 | 19,588,402 | 2021-06-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Heparin-induced thrombocytopenia'. | Anti-neutrophil cytoplasmic antibody-associated vasculitis accompanied by type II heparin-induced thrombocytopenia resulting in asymptomatic cerebral infarction: a case report.
Heparin-induced thrombocytopenia (HIT) involves platelet activation and aggregation caused by heparin or HIT antibodies associated with poor su... | CYCLOPHOSPHAMIDE, HEPARIN SODIUM, METHYLPREDNISOLONE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34126959 | 19,588,402 | 2021-06-14 |
What is the weight of the patient? | Anti-neutrophil cytoplasmic antibody-associated vasculitis accompanied by type II heparin-induced thrombocytopenia resulting in asymptomatic cerebral infarction: a case report.
Heparin-induced thrombocytopenia (HIT) involves platelet activation and aggregation caused by heparin or HIT antibodies associated with poor su... | 44.6 kg. | Weight | CC BY | 34126959 | 19,588,402 | 2021-06-14 |
What was the administration route of drug 'CYCLOPHOSPHAMIDE'? | Anti-neutrophil cytoplasmic antibody-associated vasculitis accompanied by type II heparin-induced thrombocytopenia resulting in asymptomatic cerebral infarction: a case report.
Heparin-induced thrombocytopenia (HIT) involves platelet activation and aggregation caused by heparin or HIT antibodies associated with poor su... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34126959 | 19,588,402 | 2021-06-14 |
What was the administration route of drug 'PREDNISOLONE'? | Anti-neutrophil cytoplasmic antibody-associated vasculitis accompanied by type II heparin-induced thrombocytopenia resulting in asymptomatic cerebral infarction: a case report.
Heparin-induced thrombocytopenia (HIT) involves platelet activation and aggregation caused by heparin or HIT antibodies associated with poor su... | Oral | DrugAdministrationRoute | CC BY | 34126959 | 19,588,402 | 2021-06-14 |
What was the dosage of drug 'CYCLOPHOSPHAMIDE'? | Anti-neutrophil cytoplasmic antibody-associated vasculitis accompanied by type II heparin-induced thrombocytopenia resulting in asymptomatic cerebral infarction: a case report.
Heparin-induced thrombocytopenia (HIT) involves platelet activation and aggregation caused by heparin or HIT antibodies associated with poor su... | 350 mg (milligrams). | DrugDosage | CC BY | 34126959 | 19,588,402 | 2021-06-14 |
What was the outcome of reaction 'Heparin-induced thrombocytopenia'? | Anti-neutrophil cytoplasmic antibody-associated vasculitis accompanied by type II heparin-induced thrombocytopenia resulting in asymptomatic cerebral infarction: a case report.
Heparin-induced thrombocytopenia (HIT) involves platelet activation and aggregation caused by heparin or HIT antibodies associated with poor su... | Recovering | ReactionOutcome | CC BY | 34126959 | 19,588,402 | 2021-06-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Encephalitis'. | Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review.
On the basis of the results of the IMBRAVE-150 trial, the combination of atezolizumab, a programmed cell death ligand 1 (PD-L1) antibody, as well as bevacizumab, a vascular endothelial growth facto... | ATEZOLIZUMAB, BEVACIZUMAB | DrugsGivenReaction | CC BY | 34128898 | 19,529,532 | 2021-06-18 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review.
On the basis of the results of the IMBRAVE-150 trial, the combination of atezolizumab, a programmed cell death ligand 1 (PD-L1) antibody, as well as bevacizumab, a vascular endothelial growth facto... | ATEZOLIZUMAB, BEVACIZUMAB | DrugsGivenReaction | CC BY | 34128898 | 19,529,532 | 2021-06-18 |
What was the dosage of drug 'ATEZOLIZUMAB'? | Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review.
On the basis of the results of the IMBRAVE-150 trial, the combination of atezolizumab, a programmed cell death ligand 1 (PD-L1) antibody, as well as bevacizumab, a vascular endothelial growth facto... | 1200 MG, OVER 2 HOURS | DrugDosageText | CC BY | 34128898 | 19,529,532 | 2021-06-18 |
What was the dosage of drug 'BEVACIZUMAB'? | Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review.
On the basis of the results of the IMBRAVE-150 trial, the combination of atezolizumab, a programmed cell death ligand 1 (PD-L1) antibody, as well as bevacizumab, a vascular endothelial growth facto... | 15 MG/KG OVER 90 MINUTES) | DrugDosageText | CC BY | 34128898 | 19,529,532 | 2021-06-18 |
What was the outcome of reaction 'Encephalitis'? | Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review.
On the basis of the results of the IMBRAVE-150 trial, the combination of atezolizumab, a programmed cell death ligand 1 (PD-L1) antibody, as well as bevacizumab, a vascular endothelial growth facto... | Fatal | ReactionOutcome | CC BY | 34128898 | 19,529,532 | 2021-06-18 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Blood creatinine increased'. | The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors?
BACKGROUND
The use of cisplatin in patients with chronic kidney disease (CKD) is risky and depends on a number of factors. The optim... | BLEOMYCIN SULFATE, CISPLATIN, ETOPOSIDE | DrugsGivenReaction | CC BY | 34128899 | 19,597,490 | 2021-06-18 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'C-reactive protein increased'. | The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors?
BACKGROUND
The use of cisplatin in patients with chronic kidney disease (CKD) is risky and depends on a number of factors. The optim... | BLEOMYCIN SULFATE, CISPLATIN, ETOPOSIDE | DrugsGivenReaction | CC BY | 34128899 | 19,486,431 | 2021-06-18 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Febrile neutropenia'. | The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors?
BACKGROUND
The use of cisplatin in patients with chronic kidney disease (CKD) is risky and depends on a number of factors. The optim... | BLEOMYCIN SULFATE, CISPLATIN, ETOPOSIDE | DrugsGivenReaction | CC BY | 34128899 | 19,597,490 | 2021-06-18 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thrombocytopenia'. | The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors?
BACKGROUND
The use of cisplatin in patients with chronic kidney disease (CKD) is risky and depends on a number of factors. The optim... | BLEOMYCIN SULFATE, CISPLATIN, ETOPOSIDE | DrugsGivenReaction | CC BY | 34128899 | 19,597,490 | 2021-06-18 |
What is the weight of the patient? | The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors?
BACKGROUND
The use of cisplatin in patients with chronic kidney disease (CKD) is risky and depends on a number of factors. The optim... | 101 kg. | Weight | CC BY | 34128899 | 19,486,431 | 2021-06-18 |
What was the administration route of drug 'BLEOMYCIN SULFATE'? | The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors?
BACKGROUND
The use of cisplatin in patients with chronic kidney disease (CKD) is risky and depends on a number of factors. The optim... | Intravenous bolus | DrugAdministrationRoute | CC BY | 34128899 | 19,486,431 | 2021-06-18 |
What was the administration route of drug 'CISPLATIN'? | The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors?
BACKGROUND
The use of cisplatin in patients with chronic kidney disease (CKD) is risky and depends on a number of factors. The optim... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34128899 | 19,486,431 | 2021-06-18 |
What was the administration route of drug 'ETOPOSIDE'? | The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors?
BACKGROUND
The use of cisplatin in patients with chronic kidney disease (CKD) is risky and depends on a number of factors. The optim... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34128899 | 19,486,431 | 2021-06-18 |
What was the outcome of reaction 'Blood creatinine increased'? | The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors?
BACKGROUND
The use of cisplatin in patients with chronic kidney disease (CKD) is risky and depends on a number of factors. The optim... | Recovered | ReactionOutcome | CC BY | 34128899 | 19,597,490 | 2021-06-18 |
What was the outcome of reaction 'Febrile neutropenia'? | The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors?
BACKGROUND
The use of cisplatin in patients with chronic kidney disease (CKD) is risky and depends on a number of factors. The optim... | Recovered | ReactionOutcome | CC BY | 34128899 | 19,597,490 | 2021-06-18 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective for unapproved indication'. | Neuropathic Corneal Pain Following LASIK Surgery: A Retrospective Case Series.
BACKGROUND
Transient dry eye symptoms have been reported following laser in situ keratomileusis (LASIK). Very rarely, patients may present with debilitating symptoms of dry eye syndrome (DES) with limited or no evidence of ocular surface dis... | CYCLOSPORINE, GABAPENTIN | DrugsGivenReaction | CC BY-NC | 34129211 | 20,189,498 | 2021-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Neuropathic Corneal Pain Following LASIK Surgery: A Retrospective Case Series.
BACKGROUND
Transient dry eye symptoms have been reported following laser in situ keratomileusis (LASIK). Very rarely, patients may present with debilitating symptoms of dry eye syndrome (DES) with limited or no evidence of ocular surface dis... | CYCLOSPORINE, GABAPENTIN | DrugsGivenReaction | CC BY-NC | 34129211 | 20,189,498 | 2021-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapy non-responder'. | Neuropathic Corneal Pain Following LASIK Surgery: A Retrospective Case Series.
BACKGROUND
Transient dry eye symptoms have been reported following laser in situ keratomileusis (LASIK). Very rarely, patients may present with debilitating symptoms of dry eye syndrome (DES) with limited or no evidence of ocular surface dis... | CYCLOSPORINE, GABAPENTIN | DrugsGivenReaction | CC BY-NC | 34129211 | 20,185,741 | 2021-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abscess'. | Cladophialophora bantiana and Nocardia farcinica infection simultaneously occurring in a kidney transplant recipient: Case report and literature review.
Solid organ transplant recipients are at increased risk of acquiring devastating infections with unusual pathogens. Nocardia are aerobic actinomycetes that affect the ... | MYCOPHENOLATE MOFETIL, PREDNISONE, TACROLIMUS, VALGANCICLOVIR | DrugsGivenReaction | CC BY | 34129286 | 20,327,200 | 2021-12 |
What was the administration route of drug 'MYCOPHENOLATE MOFETIL'? | Cladophialophora bantiana and Nocardia farcinica infection simultaneously occurring in a kidney transplant recipient: Case report and literature review.
Solid organ transplant recipients are at increased risk of acquiring devastating infections with unusual pathogens. Nocardia are aerobic actinomycetes that affect the ... | Oral | DrugAdministrationRoute | CC BY | 34129286 | 20,327,200 | 2021-12 |
What was the administration route of drug 'MYCOPHENOLIC ACID'? | Cladophialophora bantiana and Nocardia farcinica infection simultaneously occurring in a kidney transplant recipient: Case report and literature review.
Solid organ transplant recipients are at increased risk of acquiring devastating infections with unusual pathogens. Nocardia are aerobic actinomycetes that affect the ... | Oral | DrugAdministrationRoute | CC BY | 34129286 | 20,385,984 | 2021-12 |
What was the administration route of drug 'TACROLIMUS'? | Cladophialophora bantiana and Nocardia farcinica infection simultaneously occurring in a kidney transplant recipient: Case report and literature review.
Solid organ transplant recipients are at increased risk of acquiring devastating infections with unusual pathogens. Nocardia are aerobic actinomycetes that affect the ... | Oral | DrugAdministrationRoute | CC BY | 34129286 | 20,385,984 | 2021-12 |
What was the administration route of drug 'VALGANCICLOVIR'? | Cladophialophora bantiana and Nocardia farcinica infection simultaneously occurring in a kidney transplant recipient: Case report and literature review.
Solid organ transplant recipients are at increased risk of acquiring devastating infections with unusual pathogens. Nocardia are aerobic actinomycetes that affect the ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34129286 | 20,385,984 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abscess bacterial'. | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | CIPROFLOXACIN, CYCLOSPORINE, FLUCONAZOLE, METHOTREXATE, PREDNISOLONE, SULFAMETHOXAZOLE\TRIMETHOPRIM, VALACYCLOVIR HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 34129542 | 19,727,687 | 2021-06-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acute graft versus host disease in skin'. | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | CYCLOSPORINE, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 34129542 | 19,796,989 | 2021-06-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Chronic graft versus host disease in skin'. | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | CYCLOSPORINE, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 34129542 | 19,796,989 | 2021-06-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Chronic graft versus host disease'. | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | CYCLOSPORINE, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 34129542 | 19,796,989 | 2021-06-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease recurrence'. | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | BUSULFAN, CIPROFLOXACIN, CYCLOPHOSPHAMIDE, CYCLOSPORINE, FLUCONAZOLE, METHOTREXATE, PREDNISOLONE, SULFAMETHOXAZOLE\TRIMETHOPRIM, VALACYCLOVIR HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 34129542 | 19,729,695 | 2021-06-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Graft versus host disease in skin'. | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | CYCLOSPORINE, METHOTREXATE SODIUM | DrugsGivenReaction | CC BY-NC-ND | 34129542 | 19,514,731 | 2021-06-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nocardiosis'. | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | CIPROFLOXACIN, CYCLOSPORINE, FLUCONAZOLE, METHOTREXATE, PREDNISOLONE, SULFAMETHOXAZOLE\TRIMETHOPRIM, VALACYCLOVIR HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 34129542 | 19,727,687 | 2021-06-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pleural effusion'. | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | CIPROFLOXACIN, CYCLOSPORINE, FLUCONAZOLE, METHOTREXATE, PREDNISOLONE, SULFAMETHOXAZOLE\TRIMETHOPRIM, VALACYCLOVIR HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 34129542 | 19,727,687 | 2021-06-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | CYCLOSPORINE, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 34129542 | 19,796,989 | 2021-06-15 |
What was the administration route of drug 'CYCLOSPORINE'? | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34129542 | 19,727,687 | 2021-06-15 |
What was the administration route of drug 'SULFAMETHOXAZOLE\TRIMETHOPRIM'? | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 34129542 | 19,727,687 | 2021-06-15 |
What was the dosage of drug 'BUSULFAN'? | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | 3.2 MILLIGRAM/KILOGRAM, DAILY | DrugDosageText | CC BY-NC-ND | 34129542 | 19,729,695 | 2021-06-15 |
What was the dosage of drug 'CYCLOPHOSPHAMIDE'? | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | 60 MILLIGRAM/KILOGRAM, DAILY | DrugDosageText | CC BY-NC-ND | 34129542 | 19,729,695 | 2021-06-15 |
What was the dosage of drug 'METHOTREXATE SODIUM'? | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | UNK (CONVENTIONAL SHORT?TERM) | DrugDosageText | CC BY-NC-ND | 34129542 | 19,514,731 | 2021-06-15 |
What was the dosage of drug 'METHOTREXATE'? | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | UNK, UNKNOWN | DrugDosageText | CC BY-NC-ND | 34129542 | 19,796,989 | 2021-06-15 |
What was the dosage of drug 'SULFAMETHOXAZOLE\TRIMETHOPRIM'? | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | 320/1600 MG/DAY | DrugDosageText | CC BY-NC-ND | 34129542 | 19,729,695 | 2021-06-15 |
What was the outcome of reaction 'Abscess bacterial'? | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | Recovered | ReactionOutcome | CC BY-NC-ND | 34129542 | 19,727,687 | 2021-06-15 |
What was the outcome of reaction 'Acute graft versus host disease in skin'? | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | Recovered | ReactionOutcome | CC BY-NC-ND | 34129542 | 19,796,989 | 2021-06-15 |
What was the outcome of reaction 'Drug ineffective'? | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | Recovered | ReactionOutcome | CC BY-NC-ND | 34129542 | 19,514,731 | 2021-06-15 |
What was the outcome of reaction 'Graft versus host disease in gastrointestinal tract'? | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | Recovered | ReactionOutcome | CC BY-NC-ND | 34129542 | 19,796,989 | 2021-06-15 |
What was the outcome of reaction 'Graft versus host disease in skin'? | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | Recovered | ReactionOutcome | CC BY-NC-ND | 34129542 | 19,514,731 | 2021-06-15 |
What was the outcome of reaction 'Nocardiosis'? | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | Recovered | ReactionOutcome | CC BY-NC-ND | 34129542 | 19,727,687 | 2021-06-15 |
What was the outcome of reaction 'Pleural effusion'? | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | Recovered | ReactionOutcome | CC BY-NC-ND | 34129542 | 19,727,687 | 2021-06-15 |
What was the outcome of reaction 'Renal impairment'? | Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient.
BACKGROUND Nocardia infections have rarely been reported in hematopoietic stem cell transplantation (HSCT) patients, who usually receive the prophylactic use of sulfamethoxazole/trimethoprim (ST) against Pneumo... | Recovering | ReactionOutcome | CC BY-NC-ND | 34129542 | 19,737,828 | 2021-06-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypersensitivity'. | Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxis.
Biologic agents (BA) are able to induce an adaptive immune response in a proportion of exposed patients with the onset of anti-drug antibodies (ADA), which are usually responsible for hypers... | TOCILIZUMAB | DrugsGivenReaction | CC BY | 34131173 | 19,464,060 | 2021-06-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Myeloproliferative neoplasm'. | Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxis.
Biologic agents (BA) are able to induce an adaptive immune response in a proportion of exposed patients with the onset of anti-drug antibodies (ADA), which are usually responsible for hypers... | TOCILIZUMAB | DrugsGivenReaction | CC BY | 34131173 | 19,464,060 | 2021-06-15 |
What was the dosage of drug 'TOCILIZUMAB'? | Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxis.
Biologic agents (BA) are able to induce an adaptive immune response in a proportion of exposed patients with the onset of anti-drug antibodies (ADA), which are usually responsible for hypers... | 300 mg (milligrams). | DrugDosage | CC BY | 34131173 | 19,464,060 | 2021-06-15 |
What was the administration route of drug 'RIBAVIRIN'? | Hepatitis C Treatment Outcomes in Persons With HIV and Decompensated Cirrhosis Using a Collaborative Multidisciplinary HIV-Centered Approach.
Fifty-four consecutive persons with HIV co-infected with hepatitis C virus (HCV) and liver decompensation were treated with direct-acting antivirals (DAA). The HCV treatment was ... | Oral | DrugAdministrationRoute | CC BY-NC | 34132142 | 19,774,574 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | Creutzfeldt-Jakob disease in pregnancy: the use of modified RT-QuIC to determine infectivity in placental tissues.
Sporadic Creutzfeldt-Jakob Disease (sCJD) rarely affects women of childbearing age. There is currently no evidence of vertical transmission. Given the biosafety implications of performing Caesarean section... | HYDROXYCHLOROQUINE | DrugsGivenReaction | CC BY | 34132175 | 19,990,224 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Exposure during pregnancy'. | Creutzfeldt-Jakob disease in pregnancy: the use of modified RT-QuIC to determine infectivity in placental tissues.
Sporadic Creutzfeldt-Jakob Disease (sCJD) rarely affects women of childbearing age. There is currently no evidence of vertical transmission. Given the biosafety implications of performing Caesarean section... | HYDROXYCHLOROQUINE | DrugsGivenReaction | CC BY | 34132175 | 19,990,224 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Premature delivery'. | Creutzfeldt-Jakob disease in pregnancy: the use of modified RT-QuIC to determine infectivity in placental tissues.
Sporadic Creutzfeldt-Jakob Disease (sCJD) rarely affects women of childbearing age. There is currently no evidence of vertical transmission. Given the biosafety implications of performing Caesarean section... | HYDROXYCHLOROQUINE | DrugsGivenReaction | CC BY | 34132175 | 19,990,224 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acute myeloid leukaemia'. | Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy.
Patients with relapsed/refractory acute myeloid leukaemia (AML), ineligible for intensive chemotherapy and allogeneic stem cell transplantation, have a dismal prognosis. For su... | AZACITIDINE, OLAPARIB | DrugsGivenReaction | CC BY | 34132464 | 20,801,956 | 2021-06-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Blast cell count increased'. | Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy.
Patients with relapsed/refractory acute myeloid leukaemia (AML), ineligible for intensive chemotherapy and allogeneic stem cell transplantation, have a dismal prognosis. For su... | AZACITIDINE, OLAPARIB | DrugsGivenReaction | CC BY | 34132464 | 19,498,726 | 2021-06-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug resistance'. | Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy.
Patients with relapsed/refractory acute myeloid leukaemia (AML), ineligible for intensive chemotherapy and allogeneic stem cell transplantation, have a dismal prognosis. For su... | AZACITIDINE, OLAPARIB | DrugsGivenReaction | CC BY | 34132464 | 20,777,276 | 2021-06-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Infection'. | Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy.
Patients with relapsed/refractory acute myeloid leukaemia (AML), ineligible for intensive chemotherapy and allogeneic stem cell transplantation, have a dismal prognosis. For su... | AZACITIDINE, OLAPARIB | DrugsGivenReaction | CC BY | 34132464 | 19,983,229 | 2021-06-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Leukocytosis'. | Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy.
Patients with relapsed/refractory acute myeloid leukaemia (AML), ineligible for intensive chemotherapy and allogeneic stem cell transplantation, have a dismal prognosis. For su... | AZACITIDINE, OLAPARIB | DrugsGivenReaction | CC BY | 34132464 | 19,498,726 | 2021-06-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy.
Patients with relapsed/refractory acute myeloid leukaemia (AML), ineligible for intensive chemotherapy and allogeneic stem cell transplantation, have a dismal prognosis. For su... | AZACITIDINE, OLAPARIB | DrugsGivenReaction | CC BY | 34132464 | 20,801,956 | 2021-06-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Treatment failure'. | Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy.
Patients with relapsed/refractory acute myeloid leukaemia (AML), ineligible for intensive chemotherapy and allogeneic stem cell transplantation, have a dismal prognosis. For su... | AZACITIDINE, OLAPARIB | DrugsGivenReaction | CC BY | 34132464 | 19,983,229 | 2021-06-16 |
What was the administration route of drug 'OLAPARIB'? | Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy.
Patients with relapsed/refractory acute myeloid leukaemia (AML), ineligible for intensive chemotherapy and allogeneic stem cell transplantation, have a dismal prognosis. For su... | Oral | DrugAdministrationRoute | CC BY | 34132464 | 20,801,956 | 2021-06-16 |
What was the outcome of reaction 'Acute myeloid leukaemia'? | Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy.
Patients with relapsed/refractory acute myeloid leukaemia (AML), ineligible for intensive chemotherapy and allogeneic stem cell transplantation, have a dismal prognosis. For su... | Fatal | ReactionOutcome | CC BY | 34132464 | 20,801,956 | 2021-06-16 |
What was the outcome of reaction 'Infection'? | Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy.
Patients with relapsed/refractory acute myeloid leukaemia (AML), ineligible for intensive chemotherapy and allogeneic stem cell transplantation, have a dismal prognosis. For su... | Fatal | ReactionOutcome | CC BY | 34132464 | 19,983,229 | 2021-06-16 |
What was the outcome of reaction 'Treatment failure'? | Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy.
Patients with relapsed/refractory acute myeloid leukaemia (AML), ineligible for intensive chemotherapy and allogeneic stem cell transplantation, have a dismal prognosis. For su... | Fatal | ReactionOutcome | CC BY | 34132464 | 19,983,229 | 2021-06-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haematuria'. | Successful endovascular stenting of a bleeding external iliac vein mycotic aneurysm in an oncologic patient: a case report.
BACKGROUND
Mycotic aneurysms are rare vascular lesions, occurring in 0.6-2% of arterial aneurysms but with no reported venous cases. Venous aneurysms unrelated to an underlying infectious process ... | ENOXAPARIN, HEPARIN SODIUM | DrugsGivenReaction | CC BY | 34132912 | 19,945,649 | 2021-06-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Successful endovascular stenting of a bleeding external iliac vein mycotic aneurysm in an oncologic patient: a case report.
BACKGROUND
Mycotic aneurysms are rare vascular lesions, occurring in 0.6-2% of arterial aneurysms but with no reported venous cases. Venous aneurysms unrelated to an underlying infectious process ... | AVIBACTAM SODIUM\CEFTAZIDIME, DAPTOMYCIN, HUMAN RED BLOOD CELL, METRONIDAZOLE | DrugsGivenReaction | CC BY | 34132912 | 19,901,933 | 2021-06-16 |
What was the administration route of drug 'AVIBACTAM SODIUM\CEFTAZIDIME'? | Successful endovascular stenting of a bleeding external iliac vein mycotic aneurysm in an oncologic patient: a case report.
BACKGROUND
Mycotic aneurysms are rare vascular lesions, occurring in 0.6-2% of arterial aneurysms but with no reported venous cases. Venous aneurysms unrelated to an underlying infectious process ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34132912 | 19,901,933 | 2021-06-16 |
What was the administration route of drug 'DAPTOMYCIN'? | Successful endovascular stenting of a bleeding external iliac vein mycotic aneurysm in an oncologic patient: a case report.
BACKGROUND
Mycotic aneurysms are rare vascular lesions, occurring in 0.6-2% of arterial aneurysms but with no reported venous cases. Venous aneurysms unrelated to an underlying infectious process ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34132912 | 19,901,933 | 2021-06-16 |
What was the administration route of drug 'METRONIDAZOLE'? | Successful endovascular stenting of a bleeding external iliac vein mycotic aneurysm in an oncologic patient: a case report.
BACKGROUND
Mycotic aneurysms are rare vascular lesions, occurring in 0.6-2% of arterial aneurysms but with no reported venous cases. Venous aneurysms unrelated to an underlying infectious process ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34132912 | 19,901,933 | 2021-06-16 |
What was the dosage of drug 'HEPARIN SODIUM'? | Successful endovascular stenting of a bleeding external iliac vein mycotic aneurysm in an oncologic patient: a case report.
BACKGROUND
Mycotic aneurysms are rare vascular lesions, occurring in 0.6-2% of arterial aneurysms but with no reported venous cases. Venous aneurysms unrelated to an underlying infectious process ... | UNK, DRIP | DrugDosageText | CC BY | 34132912 | 19,945,649 | 2021-06-16 |
What was the dosage of drug 'HUMAN RED BLOOD CELL'? | Successful endovascular stenting of a bleeding external iliac vein mycotic aneurysm in an oncologic patient: a case report.
BACKGROUND
Mycotic aneurysms are rare vascular lesions, occurring in 0.6-2% of arterial aneurysms but with no reported venous cases. Venous aneurysms unrelated to an underlying infectious process ... | 2 UNITS | DrugDosageText | CC BY | 34132912 | 19,901,933 | 2021-06-16 |
What was the outcome of reaction 'Haematuria'? | Successful endovascular stenting of a bleeding external iliac vein mycotic aneurysm in an oncologic patient: a case report.
BACKGROUND
Mycotic aneurysms are rare vascular lesions, occurring in 0.6-2% of arterial aneurysms but with no reported venous cases. Venous aneurysms unrelated to an underlying infectious process ... | Recovered | ReactionOutcome | CC BY | 34132912 | 19,945,649 | 2021-06-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abdominal discomfort'. | Efficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy.
Epilepsy affects about 50 million people worldwide and around 30% of these patients have refractory epilepsy, with potential consequences regarding quality of life, morbidity and premature mortality.
The aim of treatment with a... | LEVETIRACETAM, UNSPECIFIED INGREDIENT | DrugsGivenReaction | CC BY | 34133509 | 19,569,926 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Administration site reaction'. | Efficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy.
Epilepsy affects about 50 million people worldwide and around 30% of these patients have refractory epilepsy, with potential consequences regarding quality of life, morbidity and premature mortality.
The aim of treatment with a... | LEVETIRACETAM, UNSPECIFIED INGREDIENT | DrugsGivenReaction | CC BY | 34133509 | 19,569,926 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Angiopathy'. | Efficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy.
Epilepsy affects about 50 million people worldwide and around 30% of these patients have refractory epilepsy, with potential consequences regarding quality of life, morbidity and premature mortality.
The aim of treatment with a... | LEVETIRACETAM, UNSPECIFIED INGREDIENT | DrugsGivenReaction | CC BY | 34133509 | 19,569,926 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cutaneous symptom'. | Efficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy.
Epilepsy affects about 50 million people worldwide and around 30% of these patients have refractory epilepsy, with potential consequences regarding quality of life, morbidity and premature mortality.
The aim of treatment with a... | LEVETIRACETAM, UNSPECIFIED INGREDIENT | DrugsGivenReaction | CC BY | 34133509 | 19,569,926 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Ear disorder'. | Efficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy.
Epilepsy affects about 50 million people worldwide and around 30% of these patients have refractory epilepsy, with potential consequences regarding quality of life, morbidity and premature mortality.
The aim of treatment with a... | LEVETIRACETAM, UNSPECIFIED INGREDIENT | DrugsGivenReaction | CC BY | 34133509 | 19,569,926 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Eye disorder'. | Efficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy.
Epilepsy affects about 50 million people worldwide and around 30% of these patients have refractory epilepsy, with potential consequences regarding quality of life, morbidity and premature mortality.
The aim of treatment with a... | LEVETIRACETAM, UNSPECIFIED INGREDIENT | DrugsGivenReaction | CC BY | 34133509 | 19,569,926 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Infection'. | Efficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy.
Epilepsy affects about 50 million people worldwide and around 30% of these patients have refractory epilepsy, with potential consequences regarding quality of life, morbidity and premature mortality.
The aim of treatment with a... | LEVETIRACETAM, UNSPECIFIED INGREDIENT | DrugsGivenReaction | CC BY | 34133509 | 19,569,926 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Injury'. | Efficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy.
Epilepsy affects about 50 million people worldwide and around 30% of these patients have refractory epilepsy, with potential consequences regarding quality of life, morbidity and premature mortality.
The aim of treatment with a... | LEVETIRACETAM, UNSPECIFIED INGREDIENT | DrugsGivenReaction | CC BY | 34133509 | 19,569,926 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Mental disorder'. | Efficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy.
Epilepsy affects about 50 million people worldwide and around 30% of these patients have refractory epilepsy, with potential consequences regarding quality of life, morbidity and premature mortality.
The aim of treatment with a... | LEVETIRACETAM, UNSPECIFIED INGREDIENT | DrugsGivenReaction | CC BY | 34133509 | 19,569,926 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metabolic disorder'. | Efficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy.
Epilepsy affects about 50 million people worldwide and around 30% of these patients have refractory epilepsy, with potential consequences regarding quality of life, morbidity and premature mortality.
The aim of treatment with a... | LEVETIRACETAM, UNSPECIFIED INGREDIENT | DrugsGivenReaction | CC BY | 34133509 | 19,569,926 | 2021-04 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.